The Medicare prescription drug benefit that narrowly passed Congress in November fails to rein in runaway prescription drug costs, which recently have grown 17 percent per year, seven times the rate of inflation. In fact, the measure actually prohibits the government from negotiating deep prescription drug discounts for seniors, even though other federal departments, including the Veterans Administration and the Department of Defense, have achieved significant savings through direct negotiations with drug companies.